AU2026400A - Treatment of myelogenous leukemia - Google Patents

Treatment of myelogenous leukemia

Info

Publication number
AU2026400A
AU2026400A AU20264/00A AU2026400A AU2026400A AU 2026400 A AU2026400 A AU 2026400A AU 20264/00 A AU20264/00 A AU 20264/00A AU 2026400 A AU2026400 A AU 2026400A AU 2026400 A AU2026400 A AU 2026400A
Authority
AU
Australia
Prior art keywords
treatment
myelogenous leukemia
myelogenous
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU20264/00A
Inventor
Suresh K. Jain
Lyuba Varticovski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Elizabeths Medical Center of Boston Inc
Original Assignee
St Elizabeths Medical Ct
St Elizabeths Medical Center of Boston Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Elizabeths Medical Ct, St Elizabeths Medical Center of Boston Inc filed Critical St Elizabeths Medical Ct
Publication of AU2026400A publication Critical patent/AU2026400A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0093—Purging against cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU20264/00A 1998-11-19 1999-11-19 Treatment of myelogenous leukemia Abandoned AU2026400A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10913698P 1998-11-19 1998-11-19
US60109136 1998-11-19
PCT/US1999/027392 WO2000028813A1 (en) 1998-11-19 1999-11-19 Treatment of myelogenous leukemia

Publications (1)

Publication Number Publication Date
AU2026400A true AU2026400A (en) 2000-06-05

Family

ID=22325989

Family Applications (1)

Application Number Title Priority Date Filing Date
AU20264/00A Abandoned AU2026400A (en) 1998-11-19 1999-11-19 Treatment of myelogenous leukemia

Country Status (2)

Country Link
AU (1) AU2026400A (en)
WO (1) WO2000028813A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE526396T1 (en) * 2004-04-23 2011-10-15 Hema Quebec METHOD FOR EXPANSION OF UMBILICAL CORD BLOOD CELLS
US8501397B2 (en) * 2009-07-24 2013-08-06 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Enrichment of stem cells from adult tissues
EP3366703B1 (en) * 2017-02-28 2019-04-03 Ralf Kleef Immune checkpoint therapy with hyperthermia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950470A (en) * 1986-10-06 1990-08-21 Board Of Regents, The University Of Texas System Methods and compositions employing interferon-gamma

Also Published As

Publication number Publication date
WO2000028813A9 (en) 2000-11-09
WO2000028813A1 (en) 2000-05-25

Similar Documents

Publication Publication Date Title
EP1066018B8 (en) Hair treatment compositions
AU2212299A (en) Compositions and methods for the treatment of tumor
AU2882299A (en) Anti-asthma therapy
AU3891299A (en) Combination therapy for treatment of depression
AU1772399A (en) Well treatment
AU1142600A (en) Catheter
AU5547000A (en) Novel treatment
AU4556800A (en) Novel treatment
AU5342099A (en) Dental treatment methods
AU2026400A (en) Treatment of myelogenous leukemia
AU5552400A (en) Treatment of cancer
AUPQ367699A0 (en) Treatment of cancer
GB9819999D0 (en) Treatment of cancer
AUPO832597A0 (en) Wound treatment compositions
AU2619199A (en) Treatment of waxes
AU5097099A (en) Methods and compositions for cancer treatment
AU3961899A (en) Chemotherapeutic treatment
AU1579700A (en) Cytokine combination therapy
AU5524399A (en) Inorgasmia treatment
AUPP229598A0 (en) Treatment of sunburn
AU6112299A (en) Treatment of effluents
PL346528A1 (en) Treatment of depression
AUPP472798A0 (en) Dental treatment
AUPP860099A0 (en) Treatment of feeds
AU6523898A (en) Treatment chamber

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase